Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series
Oing, Christoph Hentrich, M Lorch, A Glaser, D Rumpold, H Ochsenreither, S Richter, S Dieing, A Zsch–abitz, S Pereira, Ronnie R
Oing, Christoph
Hentrich, M
Lorch, A
Glaser, D
Rumpold, H
Ochsenreither, S
Richter, S
Dieing, A
Zsch–abitz, S
Pereira, Ronnie R
Citations
Altmetric:
Abstract
PURPOSE:
Outcomes of multiply relapsed, refractory germ-cell tumour (GCT) patients remain poor with an overall survival (OS) of a few months only. Thus, new therapeutic advances are urgently needed. Cabazitaxel has shown preclinical activity in platinum-resistant GCT models. Here, we report the first clinical case series of cabazitaxel treatment for platinum-refractory GCT.
METHODS:
Data of multiply relapsed GCT patients receiving single-agent cabazitaxel were retrospectively analysed. Endpoints included 12-week progression-free survival (PFS) rate, disease control rate, tumour marker responses, median PFS and OS, and toxicity.
RESULTS:
Cabazitaxel showed limited activity in 13 heavily pre-treated GCT patients. After a median follow-up of 23 weeks (IQR 29), 69% of patients were deceased. A median of 2 cycles of cabazitaxel (range 1-7) were applied. The 12-week PFS rate was 31%. Median PFS and OS were 7 and 23 weeks, respectively. Two patients achieved objective responses (15%), three patients (23%) achieved a tumour marker decline?³?50%, and the disease control rate was 39%. Cabazitaxel was well tolerated. CTCAE¡ III-IV haemato-toxicity was most common (54%), and dose reductions were scarce (15%).
CONCLUSION:
In this case series, cabazitaxel showed limited activity in heavily pre-treated GCT patients. Two-phase II studies are underway (NCT02115165, NCT02478502) prospectively assessing cabazitaxel in multiply relapsed GCTs.
Description
Date
2019
Publisher
Collections
Keywords
Type
Article
Citation
Oing C, Hentrich M, Lorch A, Glaser D, Rumpold H, Ochsenreither S, et al. Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series. J Cancer Res Clin Oncol. 2019:10.